active ingredients: levodopa, carbidopa;
1 tablet contains levodopa 250 mg, carbidopa 25 mg;
auxiliary substances: corn starch, corn starch, indigocarmine dye (E 132), magnesium stearate, microcrystalline cellulose.
Levocom Dosage form
Basic physical and chemical properties: blue tablets interspersed, round, with a notch.
Levocom Pharmacotherapeutic group
Antiparkinsonian drugs. Dopaminergic drugs. DOPA and derivatives. Levodopa with a decarboxylase inhibitor. ATX code N04B A02.
Levokom is a combined antiparkinsonian drug, which includes levodopa, a metabolic precursor of dopamine, and an inhibitor of peripheral dopa-decarboxylase, carbidopa.
The symptoms of Parkinson’s disease are probably associated with an insufficient amount of dopamine. Normally, dopamine acts as a neurotransmitter and is produced in certain brain cells that control muscle activity. Movement disorders are considered a consequence of dopamine deficiency.
The antiparkinsonian effect of levodopa is due to its conversion to dopamine by decarboxylation directly into the central nervous system (CNS), which eliminates dopamine deficiency in nerve cells.
Carbidopa, does not penetrate the blood-brain barrier, prevents extracerebral decarboxylation of levodopa, due to which the flow of levodopa into the brain and its conversion into dopamine in the central nervous system increases, which helps to reduce the symptoms of Parkinson’s disease in many patients.
Levodopa is rapidly absorbed from the gastrointestinal tract and metabolized. It is mainly converted to dopamine, adrenaline and norepinephrine and, ultimately, to hydroxyphenylocytic, homovanillic and vanillilmigdalic acids. 3-O-methyldopa is found in blood plasma and cerebrospinal fluid. The plasma half-life of levodopa is approximately 50 minutes. With the combined use of carbidopa and levodopa, the half-life of levodopa increases to 1.5 hours. All metabolites of carbidopa and levodopa are excreted in the urine.
Established hypersensitivity to any component of the drug.
The simultaneous use of non-selective MAO inhibitors (MAO) (the use of these drugs should be discontinued at least 2 weeks before the appointment of Levokom treatment). The drug can be used only with selective MAO-B inhibitors in recommended doses (for example, with selegiline HCl).
Severe hepatic and renal impairment. Severe heart failure. Severe cardiac arrhythmia. Acute stroke. Conditions in which adrenergic drugs are contraindicated (eg, pheochromocytoma, hyperthyroidism, Cushing’s syndrome). Suspicious undiagnosed skin lesions (dermatoses) or a history of melanoma. Glaucoma.